Latest Regulatory Process News

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Rokeby Resources (ASX:RKB) has secured the Omeo Gold Project in Victoria, adding a historical resource of 320,000 ounces at 4.0 g/t Au and launching a $4 million capital raise. The acquisition ushers in leadership changes and sets a clear path for resource expansion.

Horizon Oil has crossed the crucial 50.1% acceptance threshold in its off-market bid for Cue Energy, removing a key condition from the offer. Meanwhile, the Mereenie joint venture suspends planned drilling after gas sales talks with Northern Territory’s Power and Water Corporation expire.

Silver Mines has delivered promising exploration results from its Calico North and Kramer Hills projects in California, with standout silver and barite assays supporting imminent drilling campaigns.

Ardea Resources’ Kalgoorlie Nickel Project has been selected for the Australian Government’s Investor Front Door pilot, providing enhanced regulatory support and access to government financing to advance the project’s development.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

NH3 Clean Energy has entered a pivotal phase in its WAH2 Project development, partnering with global engineering giant Linde and progressing funding discussions to secure up to A$567 million. This collaboration aims to reduce capital and operational risks as the project moves closer to a final investment decision.

PEXA Group has dismissed any undisclosed information behind its recent share price drop, attributing market moves to a preliminary IPART pricing consultation paper.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

Sequoia Financial Group is actively reviewing its retail licensee services, focusing on its subsidiary InterPrac Financial Planning, with potential structural changes or a sale under consideration amid shifting platform provider relationships.

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Peregrine Gold Limited has announced significant progress across its Pilbara projects, including new sampling programs targeting gold anomalies and approvals for drilling at key prospects. The company’s latest assays and heritage agreements set the stage for upcoming exploration activities.